North America drug discovery market is expected to grow by 7.9% annually in the forecast period and reach $41.44 billion by 2030 driven by the rising demand for specialty medicines, the surge in lifestyle-oriented diseases and the advancements in technology, the growing elderly population and the rising healthcare expenses, rising expenditure on R&D, and expiration of patents.
Highlighted with 27 tables and 60 figures, this 117-page report “North America Drug Discovery Market 2020-2030 by Drug Type (Small Molecule, Biologics), Service (Medicinal, Biological, DMPK), Process, Technology, Therapeutic Area, End User, and Country: Trend Forecast and Growth Opportunity” is based on a comprehensive research of the entire North America drug discovery market and all its sub-segments through extensively detailed classifications. Profound analysis and assessment are generated from premium primary and secondary information sources with inputs derived from industry professionals across the value chain. The report is based on studies on 2017-2019 and provides estimate for 2020 and forecast from 2021 till 2030 with 2019 as the base year (Year 2020 is not appropriate for research base due to the outbreak of COVID-19).
In-depth qualitative analyses include identification and investigation of the following aspects:
• Market Structure
• Growth Drivers
• Restraints and Challenges
• Emerging Product Trends & Market Opportunities
• Porter’s Fiver Forces
The trend and outlook of North America market is forecast in optimistic, balanced, and conservative view by taking into account of COVID-19. The balanced (most likely) projection is used to quantify North America drug discovery market in every aspect of the classification from perspectives of Drug Type, Service, Process, Technology, Therapeutic Area, End User, and Country.
Based on Drug Type, the North America market is segmented into the following sub-markets with annual revenue ($ mn) for 2019-2030 included in each section.
• Small Molecule Drugs
• Biologic Drugs
Based on Service, the North America market is segmented into the following sub-markets with annual revenue ($ mn) for 2019-2030 included in each section.
• Medicinal Chemical Services
• Biological Services
• Drug Metabolism and Pharmacokinetics (DMPK) Services
• Other Pharmaceutical Services
Based on Process, the North America market is segmented into the following sub-markets with annual revenue ($ mn) for 2019-2030 included in each section.
• Target Selection
• Target Validation
• Hit-To-Lead Identification
• Lead Optimization
• Candidate Validation
Based on Technology, the North America market is segmented into the following sub-markets with annual revenue ($ mn) for 2019-2030 included in each section.
• High Throughput Screening
• Combinatorial Chemistry
• Pharmacogenomics and Pharmacogenetics
• Nanotechnology
• Bioanalytical Instruments
• Biochips
• Bioinformatics
• Other Technologies
Based on Therapeutic Area, the North America market is segmented into the following sub-markets with annual revenue ($ mn) for 2019-2030 included in each section.
• Oncology
• Neurology
• Infectious and Immune System Diseases
• Digestive System Diseases
• Cardiovascular Diseases
• Diabetes
• Respiratory Disease
• Other Therapeutic Areas
Based on End User, the North America market is segmented into the following sub-markets with annual revenue ($ mn) for 2019-2030 included in each section.
• Pharmaceutical Companies
• Contract Research Organizations (CROs)
• Research Institutes
• Other End Users
Geographically, the following national/local markets are fully investigated:
• U.S.
• Canada
• Mexico
For each key country, detailed analysis and data for annual revenue ($ mn) are available for 2019-2030. The breakdown of key national markets by Drug Type, Service, and Therapeutic Area over the forecast years are also included.
The report also covers current competitive scenario and the predicted trend; and profiles key vendors including market leaders and important emerging players.
Key Players (this may not be a complete list and extra companies can be added upon request):
Abbott Laboratories Inc.
Agilent Technologies Inc.
Astrazeneca plc
Bayer AG
Charles River Laboratories International Inc.
Eli Lilly and Company
F. Hoffmann-La Roche Ltd
GlaxoSmithKline PLC
Merck & Co. Inc.
Novartis AG
Pfizer Inc.
Shimadzu Corp
Thermo Fisher Scientific Inc.
(Please note: The report will be updated before delivery so that the latest historical year is the base year and the forecast covers at least 5 years over the base year.)
1 Introduction 7
1.1 Industry Definition and Research Scope 7
1.1.1 Industry Definition 7
1.1.2 Research Scope 8
1.2 Research Methodology 11
1.2.1 Overview of Market Research Methodology 11
1.2.2 Market Assumption 12
1.2.3 Secondary Data 12
1.2.4 Primary Data 12
1.2.5 Data Filtration and Model Design 13
1.2.6 Market Size/Share Estimation 14
1.2.7 Research Limitations 15
1.3 Executive Summary 16
2 Market Overview and Dynamics 19
2.1 Market Size and Forecast 19
2.1.1 Impact of COVID-19 on World Economy 20
2.1.2 Impact of COVID-19 on the Market 23
2.2 Major Growth Drivers 25
2.3 Market Restraints and Challenges 32
2.4 Emerging Opportunities and Market Trends 35
2.5 Porter’s Fiver Forces Analysis 39
3 Segmentation of North America Market by Drug Type 43
3.1 Market Overview by Drug Type 43
3.2 Small Molecule Drugs 45
3.3 Biologic Drugs 46
4 Segmentation of North America Market by Service 47
4.1 Market Overview by Service 47
4.2 Medicinal Chemical Services 49
4.3 Biological Services 50
4.4 Drug Metabolism and Pharmacokinetics (DMPK) Services 51
4.5 Other Pharmaceutical Services 52
5 Segmentation of North America Market by Process 53
5.1 Market Overview by Process 53
5.2 Target Selection 55
5.3 Target Validation 56
5.4 Hit-To-Lead Identification 57
5.5 Lead Optimization 58
5.6 Candidate Validation 59
6 Segmentation of North America Market by Technology 60
6.1 Market Overview by Technology 60
6.2 High Throughput Screening 62
6.3 Combinatorial Chemistry 63
6.4 Pharmacogenomics and Pharmacogenetics 64
6.5 Nanotechnology 65
6.6 Bioanalytical Instruments 66
6.7 Biochips 67
6.8 Bioinformatics 68
6.9 Other Technologies 69
7 Segmentation of North America Market by Therapeutic Area 70
7.1 Market Overview by Therapeutic Area 70
7.2 Oncology 72
7.3 Neurology 73
7.4 Infectious and Immune System Diseases 74
7.5 Digestive System Diseases 75
7.6 Cardiovascular Diseases 76
7.7 Diabetes 77
7.8 Respiratory Disease 78
7.9 Other Therapeutic Areas 79
8 Segmentation of North America Market by End User 80
8.1 Market Overview by End User 80
8.2 Pharmaceutical Companies 82
8.3 Contract Research Organizations (CROs) 83
8.4 Research Institutes 84
8.5 Other End Users 85
9 North America Market 2019-2030 by Country 86
9.1 Overview of North America Market 86
9.2 U.S. 89
9.3 Canada 95
9.4 Mexico 97
10 Competitive Landscape 99
10.1 Overview of Key Vendors 99
10.2 New Product Launch, Partnership, Investment, and M&A 102
10.3 Company Profiles 103
Abbott Laboratories Inc. 103
Agilent Technologies Inc. 105
Astrazeneca plc 106
Bayer AG 107
Charles River Laboratories International Inc. 108
Eli Lilly and Company 109
F. Hoffmann-La Roche Ltd 110
GlaxoSmithKline PLC 111
Merck & Co. Inc. 112
Novartis AG 113
Pfizer Inc. 114
Shimadzu Corp 115
Thermo Fisher Scientific Inc. 116
RELATED REPORTS 117
Key Players (this may not be a complete list and extra companies can be added upon request):
Abbott Laboratories Inc.
Agilent Technologies Inc.
Astrazeneca plc
Bayer AG
Charles River Laboratories International Inc.
Eli Lilly and Company
F. Hoffmann-La Roche Ltd
GlaxoSmithKline PLC
Merck & Co. Inc.
Novartis AG
Pfizer Inc.
Shimadzu Corp
Thermo Fisher Scientific Inc.
(Please note: The report will be updated before delivery so that the latest historical year is the base year and the forecast covers at least 5 years over the base year.)
Ěý
Ěý
*If Applicable.
